Black Diamond Therapeutics, Inc. BDTX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
Black Diamond Therapeutics, Inc. (BDTX) is a healthcare company listed in the US with a market value of about $84M. In fiscal year 2025 it had revenue of $70M and net income of $22M, a net margin of 32.0%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (3/5); the weakest is future growth (0/5).
Key numbers: a 5-year average ROIC of -39%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 278% above the current price.
About Black Diamond Therapeutics
Black Diamond Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. It was profitable in 1 of the last 8 years in our data. Its share count rose by 58% over three years (dilution for shareholders). It spends 48% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- ROE above 15%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $70M | $0 | — | — | — | $0 | $0 | $0 |
| Net income | $22M | -$70M | -$82M | -$91M | -$126M | -$67M | -$35M | -$9M |
| Free cash flow | — | -$62M | -$67M | -$85M | -$103M | -$52M | -$25M | -$9M |
| EPS (diluted) | $0.39 | $-1.27 | $-1.88 | $-2.52 | $-3.47 | $-2.05 | $-16.99 | $-4.42 |
| Net margin | 31.9% | — | — | — | — | — | — | — |
| ROIC | 7.5% | -59.0% | -48.1% | -51.0% | -44.5% | -17.4% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Black Diamond Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 278% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Black Diamond Therapeutics pay a dividend?
Not currently.
Is Black Diamond Therapeutics a good stock to buy?
We do not give buy or sell advice. Black Diamond Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.